183 related articles for article (PubMed ID: 8666273)
1. Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: a comparative study.
Ilves H; Barske C; Junker U; Böhnlein E; Veres G
Gene; 1996 Jun; 171(2):203-8. PubMed ID: 8666273
[TBL] [Abstract][Full Text] [Related]
2. Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy.
Junker U; Böhnlein E; Veres G
Gene Ther; 1995 Nov; 2(9):639-46. PubMed ID: 8548553
[TBL] [Abstract][Full Text] [Related]
3. Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter.
Thompson JD; Ayers DF; Malmstrom TA; McKenzie TL; Ganousis L; Chowrira BM; Couture L; Stinchcomb DT
Nucleic Acids Res; 1995 Jun; 23(12):2259-68. PubMed ID: 7610054
[TBL] [Abstract][Full Text] [Related]
4. RNA-polymerase III-driven expression cassettes in human gene therapy.
Medina MF; Joshi S
Curr Opin Mol Ther; 1999 Oct; 1(5):580-94. PubMed ID: 11249665
[TBL] [Abstract][Full Text] [Related]
5. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
6. The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization.
Bertrand E; Castanotto D; Zhou C; Carbonnelle C; Lee NS; Good P; Chatterjee S; Grange T; Pictet R; Kohn D; Engelke D; Rossi JJ
RNA; 1997 Jan; 3(1):75-88. PubMed ID: 8990401
[TBL] [Abstract][Full Text] [Related]
7. RNA polymerase III control elements are required for trans-activation by the murine retroviral long terminal repeat sequences.
Hwang YW; Yoo NK; Yang HM; Choi SY
Biochem Biophys Res Commun; 2015 Jan; 456(1):110-5. PubMed ID: 25446107
[TBL] [Abstract][Full Text] [Related]
8. Use of a nonviral vector to express a chimeric tRNA-ribozyme against lymphocytic choriomeningitis virus: cytoplasmic accumulation of a catalytically competent transcript but minimal antiviral effect.
Gebhard JR; Perry CM; Mahadeviah S; Whitton JL
Antisense Nucleic Acid Drug Dev; 1997 Feb; 7(1):3-11. PubMed ID: 9055033
[TBL] [Abstract][Full Text] [Related]
9. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
Jayan GC; Cordelier P; Patel C; BouHamdan M; Johnson RP; Lisziewicz J; Pomerantz RJ; Strayer DS
Gene Ther; 2001 Jul; 8(13):1033-42. PubMed ID: 11438838
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression and HIV-1 inhibition of chimeric tRNA(Lys3)-ribozymes under dual U6 snRNA and tRNA promoters.
Chang Z; Westaway S; Li S; Zaia JA; Rossi JJ; Scherer LJ
Mol Ther; 2002 Oct; 6(4):481-9. PubMed ID: 12377189
[TBL] [Abstract][Full Text] [Related]
11. Localized expression of small RNA inhibitors in human cells.
Paul CP; Good PD; Li SX; Kleihauer A; Rossi JJ; Engelke DR
Mol Ther; 2003 Feb; 7(2):237-47. PubMed ID: 12597912
[TBL] [Abstract][Full Text] [Related]
12. 3'-End modification of the adenoviral VA1 gene affects its expression in human cells: consequences for the design of chimeric VA1 RNA ribozymes.
Barcellini-Couget S; Fenard D; Bertrand E; Singer RH; Lefebvre JC; Doglio A
Antisense Nucleic Acid Drug Dev; 1998 Oct; 8(5):379-90. PubMed ID: 9826265
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs.
Li MJ; Bauer G; Michienzi A; Yee JK; Lee NS; Kim J; Li S; Castanotto D; Zaia J; Rossi JJ
Mol Ther; 2003 Aug; 8(2):196-206. PubMed ID: 12907142
[TBL] [Abstract][Full Text] [Related]
14. TFIIIC determines RNA polymerase III specificity at the TATA-containing yeast U6 promoter.
Roberts S; Colbert T; Hahn S
Genes Dev; 1995 Apr; 9(7):832-42. PubMed ID: 7705660
[TBL] [Abstract][Full Text] [Related]
15. Promoter choice affects the potency of HIV-1 specific RNA interference.
Boden D; Pusch O; Lee F; Tucker L; Shank PR; Ramratnam B
Nucleic Acids Res; 2003 Sep; 31(17):5033-8. PubMed ID: 12930953
[TBL] [Abstract][Full Text] [Related]
16. Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3' end can be exported efficiently and specifically to the cytoplasm in mammalian cells.
Kuwabara T; Warashina M; Koseki S; Sano M; Ohkawa J; Nakayama K; Taira K
Nucleic Acids Res; 2001 Jul; 29(13):2780-8. PubMed ID: 11433023
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts.
Cagnon L; Rossi JJ
Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):251-61. PubMed ID: 10984119
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR.
Chuah MK; VandenDriessche T; Chang HK; Ensoli B; Morgan RA
Hum Gene Ther; 1994 Dec; 5(12):1467-75. PubMed ID: 7711139
[TBL] [Abstract][Full Text] [Related]
19. A variety of RNA polymerases II and III-dependent promoter classes is repressed by factors containing the Krüppel-associated/finger preceding box of zinc finger proteins.
Senatore B; Cafieri A; Di Marino I; Rosati M; Di Nocera PP; Grimaldi G
Gene; 1999 Jul; 234(2):381-94. PubMed ID: 10395912
[TBL] [Abstract][Full Text] [Related]
20. Utility of Epstein-Barr virus-encoded small RNA promoters for driving the expression of fusion transcripts harboring short hairpin RNAs.
Choy EY; Kok KH; Tsao SW; Jin DY
Gene Ther; 2008 Feb; 15(3):191-202. PubMed ID: 17972920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
